Related Experiment Videos
Novel 1-haloalkyl-2-nitroimidazole bioreductive alkylating agents
D C Heimbrook1, K Shyam, A C Sartorelli
1Department of Pharmacology, Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06510.
Abstract:
Solid tumors contain hypoxic cells which are relatively resistant to radiation treatment and to most forms of chemotherapy. These cells can be preferentially targeted using chemotherapeutic agents that are specifically activated by cellular reductase enzymes in the absence of oxygen. A new class of bioreductive alkylating agents based on the 2-nitroimidazole nucleus has been developed which contains a haloalkyl substituent on the N-1 position of the imidazole ring. Compounds of this series were readily reduced by mammalian NADPH-cytochrome c reductase, and reduction led to the production of an electrophilic center. This reactive component was hypothesized to be responsible for the preferential cytotoxicity of the agents of this class to hypoxic tumor cells through alkylation of cellular components.
Insights
New bioreductive alkylating agents target resistant hypoxic tumor cells. These 2-nitroimidazole compounds are activated by reductase enzymes, selectively killing cancer cells via alkylation.
Area of Science:
- Oncology
- Medicinal Chemistry
- Biochemistry
Background:
- Solid tumors often contain hypoxic cells, exhibiting resistance to conventional radiation and chemotherapy.
- Hypoxic cells present a significant challenge in cancer treatment, necessitating targeted therapeutic strategies.
Purpose of the Study:
- To develop and evaluate a novel class of bioreductive alkylating agents for selective targeting of hypoxic tumor cells.
- To investigate the mechanism of action of 2-nitroimidazole-based compounds activated under hypoxic conditions.
Main Methods:
- Synthesis of 2-nitroimidazole derivatives with a haloalkyl substituent at the N-1 position.
- Assessment of bioreductive activation by mammalian NADPH-cytochrome c reductase.
- Evaluation of selective cytotoxicity towards hypoxic tumor cells.
Main Results:
- Compounds were efficiently reduced by NADPH-cytochrome c reductase.
- Reduction generated an electrophilic center, indicating potential for alkylation.
- The agents demonstrated preferential cytotoxicity to hypoxic tumor cells.
Conclusions:
- The novel 2-nitroimidazole-based bioreductive alkylating agents show promise for selectively targeting and eliminating hypoxic tumor cells.
- Activation via reductase enzymes under hypoxia leads to alkylation and cell death, offering a new therapeutic avenue.